The Fasolati Therapeutic Platform

Three product lines. Three mechanisms. One unified architecture. A surgeon‑engineered system that treats the mouth as a controllable origin node of systemic inflammation.

LyticaPrecision Ecological Rescue

From Greek lysis — targeted dissolution. Hunt and eliminate. Spare everything else.

A two‑stage tray‑applied biofilm intervention system. Stage 1 (BREACH) uses hydrogen peroxide effervescence plus enzymatic matrix degradation — DNase I, Dispersin B, Proteinase K — to collapse biofilm architecture in 5–10 minutes. Stage 2 (HUNT) deploys bacteriophages targeting P. gingivalis, T. forsythia, and A. actinomycetemcomitans, plus recombinant endolysins and lactoferrin, delivered in a dual‑weight hyaluronic acid matrix for sustained contact and tissue support.

Stage 1 — Breach

H₂O₂ effervescence disrupts biofilm oxygen gradients. DNase I degrades extracellular DNA scaffold. Dispersin B hydrolyzes PNAG adhesin matrix. Proteinase K cleaves surface-bound adhesion proteins. Combined: 4.5 log colony reduction.

Stage 2 — Hunt

Species-specific bacteriophages bind exclusively to bacterial surface receptors. Recombinant endolysins degrade peptidoglycan from outside. Lactoferrin sequesters iron from pathogen metabolism. HA carrier ensures 4+ hours mucosal residence time.

Clinical Targets

Active periodontal disease — stages III and IV
Peri-implantitis — biofilm on titanium surfaces
Post-surgical infection control
Refractory cases non-responsive to SRP + antibiotics
LoriaMolecular Purification

From Latin luere — to purify. The original Fasolati formulation. Physical barrier, heal, hydrate, and hold.

Loria replaces chlorhexidine's indiscriminate kill with intelligent ecological remodeling. Biofilm‑dispersing enzymes dismantle the extracellular polysaccharide scaffold. Dual‑weight hyaluronic acid creates a physical barrier while driving fibroblast proliferation by 35% within 7 days. Castor oil reduces IL‑1β and TNF‑α while reinforcing pellicle lipid barriers. Bio‑adhesive film formation via pullulan and PVP ensures hours of therapeutic residence.

Barrier + Heal

High MW HA forms protective scaffolding on mucosal surface. Low MW HA penetrates deeper tissue, stimulates fibroblast proliferation, drives re-epithelialization (8/9 wounds healed in 24 hours vs 0/9 saline).

Hydrate + Hold

Dual-weight HA retains moisture at mucosal surfaces. Pullulan + PVP create cross-linked adhesion network for extended therapeutic residence. CPC at 0.05% provides selective antimicrobial baseline.

Clinical Targets

Daily oral ecology maintenance — chlorhexidine replacement
Biofilm management — prevent recolonization after treatment
Post-surgical mucosal healing support
Xerostomia (dry mouth) — sustained hydration
Distribution Architecture

Maxoral and Fasolati are not products. They're distribution tiers that determine formulation strength, regulatory class, and channel strategy.

Maxoral

Rx Grade — Professional Channel

Prescription-strength formulations. Higher enzyme concentrations, full phage payloads (when cleared), extended-release tray application. Distributed through DSOs, periodontists, oral surgeons via Henry Schein, Patterson, Benco.

Fasolati

OTC Grade — Consumer Channel

Consumer formulations optimized within OTC regulatory limits. D2C, Amazon, pharmacy, subscription. Daily Loria maintenance, Stage 1 Lytica enzyme gel. The recurring revenue engine.

The Therapeutic Cascade

Lytica and Loria are not two separate products. They are a clinical protocol.

1

Lytica Hunts

Clear the active infection. Breach the biofilm. Eliminate keystone pathogens. Reset the ecology.

↓
2

Loria Purifies

Maintain the ecology daily. Disrupt biofilm reformation. Barrier, heal, hydrate, hold. Indefinitely.

DSOs deploy this as a complete system of care. Lytica is the high-margin intervention. Loria is the recurring subscription revenue stream.